Symbols / EVAX $3.49 -5.39% Evaxion A/S
EVAX Chart
About
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 29.11M |
| Enterprise Value | 1.56B | Income | -7.71M | Sales | 7.53M |
| Book/sh | 2.04 | Cash/sh | 0.06 | Dividend Yield | — |
| Payout | 0.00% | Employees | 46 | IPO | — |
| P/E | — | Forward P/E | 87.25 | PEG | — |
| P/S | 3.87 | P/B | 1.71 | P/C | — |
| EV/EBITDA | -175.88 | EV/Sales | 207.30 | Quick Ratio | 5.71 |
| Current Ratio | 5.85 | Debt/Eq | 44.04 | LT Debt/Eq | — |
| EPS (ttm) | -1.00 | EPS next Y | 0.04 | EPS Growth | — |
| Revenue Growth | -100.00% | Earnings | 2026-03-05 09:00 | ROA | -28.23% |
| ROE | -100.17% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -122.66% | Profit Margin | -102.38% | Shs Outstand | 8.34M |
| Shs Float | 283.97M | Short Float | 0.84% | Short Ratio | 1.86 |
| Short Interest | — | 52W High | 12.15 | 52W Low | 1.20 |
| Beta | 0.20 | Avg Volume | 45.42K | Volume | 9.55K |
| Target Price | $11.25 | Recom | None | Prev Close | $3.69 |
| Price | $3.49 | Change | -5.39% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.25
Mean price target
2. Current target
$3.51
Latest analyst target
3. DCF / Fair value
$-9.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.51
Low
$9.00
High
$16.00
Mean
$11.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-10 | init | Jones Trading | — → Buy | $10 |
| 2026-03-09 | main | Lake Street | Buy → Buy | $9 |
| 2026-03-09 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-10-30 | init | Edward Jones | — → Buy | $10 |
| 2025-10-20 | main | Lake Street | Buy → Buy | $11 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-09-25 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-04-02 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-04 | main | Lake Street | Buy → Buy | $6 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-11-01 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-09-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-04-02 | up | Ladenburg Thalmann | Neutral → Buy | $8 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
- Evaxion wraps skin cancer vaccine study, with 3-year data due in 2026 - Stock Titan ue, 07 Apr 2026 12
- Evaxion Completes One-Year Extension of Phase 2 Trial for AI-Designed Melanoma Vaccine EVX-01 - TipRanks ue, 07 Apr 2026 12
- Evaxion (EVAX) wraps EVX-01 phase 2 extension with 75% response - Stock Titan ue, 07 Apr 2026 12
- Evaxion Calls April 16, 2026 AGM to Expand Capital and Warrant Authorizations - The Globe and Mail Fri, 20 Mar 2026 07
- Evaxion (NASDAQ: EVAX) director reports major share and warrant stakes - Stock Titan hu, 02 Apr 2026 20
- Evaxion A/S (EVAX) director reports shares and warrant holdings - Stock Titan hu, 02 Apr 2026 01
- Evaxion shareholders meet in Denmark on April 16 for AGM - Stock Titan hu, 19 Mar 2026 07
- Evaxion, Gates Foundation take AI polio vaccine designs to Congress - Stock Titan Mon, 30 Mar 2026 12
- AI vaccine firm Evaxion lands MSD deal worth up to $592 million - Stock Titan hu, 05 Mar 2026 08
- [Form 3/A] Evaxion A/S Amended Initial Statement of Beneficial Ownership - Stock Titan ue, 31 Mar 2026 23
- AI cancer vaccines for melanoma and deadly brain tumors on AACR stage - Stock Titan ue, 17 Mar 2026 07
- Evaxion (EVAX) director Roberto Prego discloses shares and long-dated warrants - Stock Titan Fri, 27 Mar 2026 07
- AI-driven vaccine firm Evaxion targets autoimmune diseases next globally - Stock Titan ue, 13 Jan 2026 08
- Evaxion (EVAX) CFO Form 3/A details share and warrant stakes - Stock Titan Fri, 27 Mar 2026 07
- Evaxion (EVAX) CSO Birgitte Rono details extensive warrant holdings - Stock Titan Fri, 27 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
7.53
+125.12%
|
3.34
+4480.82%
|
0.07
|
0.00
|
| Operating Revenue |
|
7.53
+125.12%
|
3.34
+4480.82%
|
0.07
|
0.00
|
| Operating Expense |
|
16.76
-7.27%
|
18.08
-18.83%
|
22.27
-11.85%
|
25.26
|
| Research And Development |
|
9.97
-4.61%
|
10.46
-12.24%
|
11.92
-30.14%
|
17.06
|
| Selling General And Administration |
|
6.49
-11.36%
|
7.32
-27.40%
|
10.08
+24.99%
|
8.06
|
| General And Administrative Expense |
|
6.49
-11.36%
|
7.32
-27.40%
|
10.08
+24.99%
|
8.06
|
| Salaries And Wages |
|
2.67
+3.32%
|
2.59
-17.37%
|
3.13
+44.67%
|
2.17
|
| Other Gand A |
|
3.81
-19.39%
|
4.73
-31.93%
|
6.95
+17.77%
|
5.90
|
| Total Expenses |
|
16.76
-7.27%
|
18.08
-18.83%
|
22.27
-11.85%
|
25.26
|
| Operating Income |
|
-9.23
+37.32%
|
-14.73
+33.63%
|
-22.20
+12.14%
|
-25.26
|
| Total Operating Income As Reported |
|
-9.23
+37.32%
|
-14.73
+33.63%
|
-22.20
+12.14%
|
-25.26
|
| EBITDA |
|
-7.12
+27.20%
|
-9.79
+54.28%
|
-21.40
+5.18%
|
-22.57
|
| Normalized EBITDA |
|
-5.75
+58.53%
|
-13.87
+35.27%
|
-21.43
+13.18%
|
-24.68
|
| Reconciled Depreciation |
|
0.61
+1.32%
|
0.61
-1.30%
|
0.61
+7.71%
|
0.57
|
| EBIT |
|
-7.74
+25.54%
|
-10.39
+52.80%
|
-22.02
+4.86%
|
-23.14
|
| Total Unusual Items |
|
-1.37
-133.59%
|
4.08
+16240.00%
|
0.03
-98.81%
|
2.11
|
| Total Unusual Items Excluding Goodwill |
|
-1.37
-133.59%
|
4.08
+16240.00%
|
0.03
-98.81%
|
2.11
|
| Net Income |
|
-7.71
+27.07%
|
-10.57
+52.24%
|
-22.12
+4.51%
|
-23.17
|
| Pretax Income |
|
-8.62
+24.13%
|
-11.36
+50.45%
|
-22.91
+4.29%
|
-23.94
|
| Net Non Operating Interest Income Expense |
|
1.99
+381.21%
|
-0.71
+4.71%
|
-0.74
+5.35%
|
-0.79
|
| Interest Expense Non Operating |
|
0.88
-8.94%
|
0.96
+7.25%
|
0.90
+12.41%
|
0.80
|
| Net Interest Income |
|
1.99
+381.21%
|
-0.71
+4.71%
|
-0.74
+5.35%
|
-0.79
|
| Interest Expense |
|
0.88
-8.94%
|
0.96
+7.25%
|
0.90
+12.41%
|
0.80
|
| Interest Income Non Operating |
|
0.30
+17.72%
|
0.25
+64.94%
|
0.15
+1084.62%
|
0.01
|
| Interest Income |
|
0.30
+17.72%
|
0.25
+64.94%
|
0.15
+1084.62%
|
0.01
|
| Other Income Expense |
|
-1.37
-133.59%
|
4.08
+16240.00%
|
0.03
-98.81%
|
2.11
|
| Gain On Sale Of Security |
|
-1.37
-133.59%
|
4.08
+16240.00%
|
0.03
-98.81%
|
2.11
|
| Tax Provision |
|
-0.91
-15.23%
|
-0.79
+0.25%
|
-0.79
-2.33%
|
-0.77
|
| Tax Rate For Calcs |
|
0.00
+42.86%
|
0.00
+75.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.14
-147.98%
|
0.29
+28495.00%
|
0.00
-98.81%
|
0.08
|
| Net Income Including Noncontrolling Interests |
|
-7.71
+27.07%
|
-10.57
+52.24%
|
-22.12
+4.51%
|
-23.17
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.71
+27.07%
|
-10.57
+52.24%
|
-22.12
+4.51%
|
-23.17
|
| Net Income From Continuing And Discontinued Operation |
|
-7.71
+27.07%
|
-10.57
+52.24%
|
-22.12
+4.51%
|
-23.17
|
| Net Income Continuous Operations |
|
-7.71
+27.07%
|
-10.57
+52.24%
|
-22.12
+4.51%
|
-23.17
|
| Normalized Income |
|
-6.47
+54.95%
|
-14.37
+35.14%
|
-22.15
+12.08%
|
-25.19
|
| Net Income Common Stockholders |
|
-7.71
+27.07%
|
-10.57
+52.24%
|
-22.12
+4.51%
|
-23.17
|
| Diluted EPS |
|
—
|
-10.00
+75.31%
|
-40.50
+17.35%
|
-49.00
|
| Basic EPS |
|
—
|
-10.00
+75.31%
|
-40.50
+17.35%
|
-49.00
|
| Basic Average Shares |
|
—
|
1.07
+96.24%
|
0.55
+15.64%
|
0.47
|
| Diluted Average Shares |
|
—
|
1.07
+96.24%
|
0.55
+15.64%
|
0.47
|
| Diluted NI Availto Com Stockholders |
|
-7.71
+27.07%
|
-10.57
+52.24%
|
-22.12
+4.51%
|
-23.17
|
| Depreciation Amortization Depletion Income Statement |
|
0.30
-0.33%
|
0.30
+9.82%
|
0.28
+90.97%
|
0.14
|
| Depreciation And Amortization In Income Statement |
|
0.30
-0.33%
|
0.30
+9.82%
|
0.28
+90.97%
|
0.14
|
| Depreciation Income Statement |
|
0.30
-0.33%
|
0.30
+9.82%
|
0.28
+90.97%
|
0.14
|
| Total Other Finance Cost |
|
-2.57
|
—
|
—
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
12.89
|
| Current Assets |
|
8.35
|
| Cash Cash Equivalents And Short Term Investments |
|
4.18
|
| Cash And Cash Equivalents |
|
4.18
|
| Receivables |
|
1.07
|
| Other Receivables |
|
0.12
|
| Taxes Receivable |
|
0.96
|
| Prepaid Assets |
|
1.69
|
| Current Deferred Assets |
|
—
|
| Restricted Cash |
|
1.40
|
| Total Non Current Assets |
|
4.54
|
| Net PPE |
|
4.34
|
| Gross PPE |
|
5.51
|
| Accumulated Depreciation |
|
-1.17
|
| Properties |
|
0.00
|
| Other Properties |
|
4.12
|
| Leases |
|
1.39
|
| Goodwill And Other Intangible Assets |
|
—
|
| Non Current Accounts Receivable |
|
0.03
|
| Non Current Deferred Assets |
|
—
|
| Non Current Deferred Taxes Assets |
|
—
|
| Non Current Prepaid Assets |
|
0.17
|
| Total Liabilities Net Minority Interest |
|
17.62
|
| Current Liabilities |
|
7.08
|
| Payables And Accrued Expenses |
|
2.69
|
| Payables |
|
2.69
|
| Accounts Payable |
|
2.69
|
| Other Payable |
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.89
|
| Current Debt And Capital Lease Obligation |
|
0.48
|
| Current Debt |
|
0.16
|
| Other Current Borrowings |
|
0.16
|
| Current Capital Lease Obligation |
|
0.33
|
| Other Current Liabilities |
|
3.02
|
| Total Non Current Liabilities Net Minority Interest |
|
10.53
|
| Long Term Debt And Capital Lease Obligation |
|
10.38
|
| Long Term Debt |
|
8.49
|
| Long Term Capital Lease Obligation |
|
1.90
|
| Long Term Provisions |
|
0.15
|
| Other Non Current Liabilities |
|
0.01
|
| Stockholders Equity |
|
-4.73
|
| Common Stock Equity |
|
-4.73
|
| Capital Stock |
|
5.90
|
| Common Stock |
|
5.90
|
| Share Issued |
|
37.90
|
| Ordinary Shares Number |
|
37.90
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
87.45
|
| Retained Earnings |
|
-107.97
|
| Gains Losses Not Affecting Retained Earnings |
|
-3.77
|
| Other Equity Adjustments |
|
—
|
| Total Equity Gross Minority Interest |
|
-4.73
|
| Total Capitalization |
|
3.76
|
| Working Capital |
|
1.27
|
| Invested Capital |
|
3.92
|
| Total Debt |
|
10.87
|
| Net Debt |
|
4.46
|
| Capital Lease Obligations |
|
2.22
|
| Net Tangible Assets |
|
-4.73
|
| Tangible Book Value |
|
-4.73
|
| Foreign Currency Translation Adjustments |
|
-3.77
|
| Other Equity Interest |
|
13.66
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.62
+48.80%
|
-12.94
+26.86%
|
-17.69
+31.36%
|
-25.77
|
| Cash Flow From Continuing Operating Activities |
|
-6.62
+48.80%
|
-12.94
+26.86%
|
-17.69
+31.36%
|
-25.77
|
| Net Income From Continuing Operations |
|
-7.71
+27.07%
|
-10.57
+52.24%
|
-22.12
+4.51%
|
-23.17
|
| Depreciation Amortization Depletion |
|
0.61
+1.32%
|
0.61
-1.30%
|
0.61
+7.71%
|
0.57
|
| Depreciation |
|
0.61
+1.32%
|
0.61
-1.30%
|
0.61
+7.71%
|
0.57
|
| Depreciation And Amortization |
|
0.61
+1.32%
|
0.61
-1.30%
|
0.61
+7.71%
|
0.57
|
| Other Non Cash Items |
|
-0.62
+80.91%
|
-3.24
-401.30%
|
1.08
+303.02%
|
-0.53
|
| Stock Based Compensation |
|
0.31
-14.01%
|
0.36
-25.47%
|
0.48
-49.15%
|
0.94
|
| Asset Impairment Charge |
|
—
|
0.00
|
0.00
-100.00%
|
0.09
|
| Deferred Tax |
|
-0.91
-11.69%
|
-0.81
+17.38%
|
-0.98
+1.40%
|
-1.00
|
| Deferred Income Tax |
|
-0.91
-11.69%
|
-0.81
+17.38%
|
-0.98
+1.40%
|
-1.00
|
| Operating Gains Losses |
|
—
|
-3.88
-1276.95%
|
-0.28
+28.61%
|
-0.40
|
| Gain Loss On Investment Securities |
|
—
|
-3.88
-1276.95%
|
-0.28
+28.61%
|
-0.40
|
| Change In Working Capital |
|
-0.14
-126.35%
|
0.52
-66.71%
|
1.56
+154.29%
|
-2.88
|
| Change In Receivables |
|
0.18
+206.59%
|
-0.17
-164.48%
|
0.26
+117.43%
|
-1.49
|
| Change In Prepaid Assets |
|
0.41
-44.84%
|
0.74
-8.23%
|
0.80
|
—
|
| Change In Payables And Accrued Expense |
|
-0.54
-764.52%
|
-0.06
-108.14%
|
0.76
+154.78%
|
-1.39
|
| Change In Payable |
|
-0.54
-764.52%
|
-0.06
-108.14%
|
0.76
+154.78%
|
-1.39
|
| Change In Account Payable |
|
-0.54
-764.52%
|
-0.06
-108.14%
|
0.76
+227.21%
|
-0.60
|
| Change In Other Working Capital |
|
-0.18
-1523.08%
|
0.01
+104.98%
|
-0.26
|
—
|
| Investing Cash Flow |
|
-0.01
-366.67%
|
-0.00
+96.77%
|
-0.09
+65.30%
|
-0.27
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
-366.67%
|
-0.00
+96.77%
|
-0.09
+65.30%
|
-0.27
|
| Net PPE Purchase And Sale |
|
-0.01
|
0.00
+100.00%
|
-0.09
+70.21%
|
-0.29
|
| Purchase Of PPE |
|
-0.01
|
0.00
+100.00%
|
-0.09
+70.21%
|
-0.29
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.02
|
| Capital Expenditure |
|
-0.01
|
—
|
-0.09
+70.21%
|
-0.29
|
| Net Investment Purchase And Sale |
|
-0.00
+0.00%
|
-0.00
+50.00%
|
-0.01
-125.00%
|
0.02
|
| Purchase Of Investment |
|
-0.00
+0.00%
|
-0.00
+50.00%
|
-0.01
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
0.02
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
—
|
0.00
|
0.00
|
0.00
|
| Financing Cash Flow |
|
22.41
+70.69%
|
13.13
+22.80%
|
10.69
+36.14%
|
7.85
|
| Cash Flow From Continuing Financing Activities |
|
22.41
+70.69%
|
13.13
+22.80%
|
10.69
+36.14%
|
7.85
|
| Net Issuance Payments Of Debt |
|
-0.75
+33.89%
|
-1.14
-79.75%
|
-0.63
-108.51%
|
7.42
|
| Issuance Of Debt |
|
0.00
|
0.00
-100.00%
|
0.07
-99.17%
|
7.85
|
| Repayment Of Debt |
|
-0.75
+33.89%
|
-1.14
-62.98%
|
-0.70
-64.39%
|
-0.42
|
| Long Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
0.07
-99.17%
|
7.85
|
| Long Term Debt Payments |
|
-0.75
+33.89%
|
-1.14
-62.98%
|
-0.70
-64.39%
|
-0.42
|
| Net Long Term Debt Issuance |
|
-0.75
+33.89%
|
-1.14
-79.75%
|
-0.63
-108.51%
|
7.42
|
| Net Common Stock Issuance |
|
23.16
+63.04%
|
14.21
+25.46%
|
11.32
+2545.56%
|
0.43
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
-100.00%
|
2.59
|
0.00
|
| Net Other Financing Charges |
|
—
|
0.06
+113.66%
|
-0.43
|
—
|
| Changes In Cash |
|
15.77
+8379.03%
|
0.19
+102.62%
|
-7.09
+61.00%
|
-18.19
|
| Effect Of Exchange Rate Changes |
|
1.51
+725.68%
|
0.18
+136.02%
|
-0.51
+35.94%
|
-0.79
|
| Beginning Cash Position |
|
5.95
+6.61%
|
5.58
-57.65%
|
13.18
-59.01%
|
32.17
|
| End Cash Position |
|
23.23
+290.36%
|
5.95
+6.61%
|
5.58
-57.65%
|
13.18
|
| Free Cash Flow |
|
-6.64
+48.72%
|
-12.94
+27.21%
|
-17.78
+31.80%
|
-26.07
|
| Common Stock Issuance |
|
23.16
+63.04%
|
14.21
+25.46%
|
11.32
+2545.56%
|
0.43
|
| Interest Paid CFO |
|
-0.11
-91.07%
|
-0.06
+13.85%
|
-0.07
+62.21%
|
-0.17
|
| Interest Received CFO |
|
0.30
+17.72%
|
0.25
+64.94%
|
0.15
+1084.62%
|
0.01
|
| Issuance Of Capital Stock |
|
23.16
+63.04%
|
14.21
+25.46%
|
11.32
+2545.56%
|
0.43
|
| Taxes Refund Paid |
|
1.63
|
0.00
-100.00%
|
1.60
+111.80%
|
0.75
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|